Peptic Ulcer Disease IV: Management

Medical management uses triple or quadruple therapy for 10 to 14 days to eradicate H. pylori. Triple therapy combines two antibiotics—metronidazole and clarithromycin—with a proton pump inhibitor. Quadruple therapy adds bismuth salts to two antibiotics, metronidazole and tetracycline, plus a PPI. This strategic combination effectively combats the infection and promotes ulcer healing.

Proton pump inhibitors (PPIs) suppress gastric acid secretion, reducing acidity and allowing ulcer healing. They are central to triple and quadruple therapy regimens for H. pylori eradication. For Zollinger-Ellison syndrome, where gastrin hypersecretion stimulates excessive acid release, PPIs effectively control gastric acid production and are the primary pharmacological treatment.

Cytoprotective drugs like sucralfate strengthen mucosal defense mechanisms by coating and protecting the esophagus, stomach, and duodenum. Unlike antacids, sucralfate works at low pH and should be administered at least 60 minutes before or after antacids to maximize effectiveness. These drugs provide short-term ulcer protection alongside acid-suppressing medications.

For patients on aspirin and nonselective NSAIDs, a 4 to 6 week pause is recommended. When aspirin continuation is essential, co-administration with a proton pump inhibitor, H2 receptor blocker, or misoprostol is advised. Misoprostol, a synthetic prostaglandin analog, specifically prevents gastric ulcers caused by NSAIDs and low-dose aspirin in chronic therapy.

Patients should avoid foods stimulating acid secretion, including spicy foods, carbonated drinks, caffeine, and alcohol. Smoking cessation is crucial because it reduces pancreatic bicarbonate secretion, increasing duodenal acidity and delaying healing. Adequate rest, stress reduction, and regular follow-up care complete the comprehensive management strategy for effective ulcer recovery.

H2 receptor blockers and antacids serve as adjunct therapy to promote ulcer healing. Antacids neutralize hydrochloric acid and reduce acid content reaching the duodenum. Some antacids like aluminum hydroxide bind bile salts, decreasing bile's damaging effects on gastric mucosa. These medications complement primary acid-suppressing and antibiotic regimens.

Octreotide is prescribed for Zollinger-Ellison syndrome, a condition characterized by gastrin hypersecretion that stimulates excessive hydrochloric acid release. This medication suppresses gastrin levels, reducing acid production. When considering surgical options, patients may benefit from understanding disease surgical management and nursing care approaches for severe cases unresponsive to medical therapy.